Hypoxia-Induced Oxidative Stress in Fatty Liver Disease: Mechanisms and Therapeutic Perspectives

Abstract

Fatty liver disease, particularly metabolic dysfunction-associated fatty liver disease (MAFLD), has become one of the most prevalent metabolic disorders worldwide. Hypoxia is increasingly recognized as a key pathological factor that exacerbates hepatic lipid accumulation, inflammation, and oxidative injury. Hepatic hypoxia may arise from obesity-induced microvascular dysfunction, excessive fat deposition, and conditions such as obstructive sleep apnea, all of which impair oxygen delivery to hepatocytes. Under hypoxic conditions, the stabilization of hypoxia-inducible factor-1α (HIF-1α) alters gene expression in lipid metabolism, inflammatory signalling, and redox balance, promoting excessive reactive oxygen species (ROS) production, mitochondrial dysfunction, and impaired antioxidant defenses. These changes exacerbate oxidative stress and lead to hepatocellular injury. Hypoxia-driven oxidative stress interacts with lipid metabolic pathways, forming a positive feedback loop that accelerates disease progression from simple steatosis to non-alcoholic steatohepatitis (NASH) and fibrosis. Clinical evidence supports this association, with studies showing that patients with intermittent or chronic hypoxia exhibit 2-3 times higher levels of liver enzymes, inflammatory mediators, and markers of fibrosis compared to controls. Despite growing understanding of the molecular interplay between hypoxia and oxidative stress, therapeutic interventions specifically targeting these mechanisms remain limited. This narrative review summarizes current evidence on how hypoxia induces oxidative stress in fatty liver disease and highlights emerging therapeutic strategies, including antioxidants, mitochondrial-targeted agents, and lifestyle interventions. These approaches show promise in slowing or preventing progression to fibrosis; however, further well-designed clinical trials are required to confirm their efficacy.